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Abstract: Background: The term “SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis) syndrome” includes a 
variety of musculoskeletal disorders associated with skin conditions; Osteitis is the most prominent skeletal lesion, 
whereas palmoplantar pustulosis and acne are the main skin lesions. Diagnosing SAPHO syndrome is difficult, because 
this syndrome is often confused with suppurative osteomyelitis, which has similar clinical and pathologic findings. 
SAPHO diagnosis is even more difficult when atypical sites are involved and there are no skin lesions. 
Patients and Methods: This case series presents five patients (3 women, 2 men), ages 27 to 44 years, who came to the 
Orthopaedic Department outpatient clinic for evaluation of pain in the humerus, clavicle, sacro-iliac joints, and/or distal 
radius, and were diagnosed with SAPHO syndrome. Clinical and radiologic findings, treatment and outcome data, with up 
to 4 years of follow-up are presented. An extensive discussion of the clinical presentation, published literature, treatment 
options and outcome of SAPHO syndrome is also included. 
Results: Once the diagnosis of SAPHO syndrome was established, treatment with antibiotics (clindamycin) and non 
steroid anti-inflammatory drugs (lornoxicam) was remarkably effective. All patients did well and remained symptom free 
for up to four years, after a 3-8 month course of treatment. 
Interpretation: SAPHO syndrome should be included in the differential diagnosis when evaluating patients with lytic, 
sclerotic, or hyperostotic bone lesions and pain. Prompt SAPHO syndrome recognition, followed by appropriate therapy 
with antibiotics and NSAIDs can produce rapid symptom resolution, while avoiding unnecessary procedures and long-
term antibiotic therapy. 
Keywords: SAPHO, synovitis, acne, pustulosis, hyperostosis, osteitis, pain, lornoxicam, clindamycin. 
INTRODUCTION 
  SAPHO (synovitis, acne, pustulosis, hyperostosis and 
osteitis) syndrome [1] is characterized by osteoarticular and 
dermatological manifestations. Chamot and co-workers first 
described in 1987 [2] “le syndrome acne pustulose 
hyperostose osteite” and introduced the acronym SAPHO, to 
designate the constellation of these five frequently combined 
disorders. The syndrome can occur at any age but usually 
appears between childhood and middle age and follows a 
prolonged relapsing and remitting course [3]. 
  Hyperostosis and osteitis are the most prominent SAPHO 
syndrome findings [4,5]. Hyperostosis appears radiologically 
as osteosclerosis, with cortical thickening, narrowing of the 
medullary canal, and external surface of the bone appearing 
expanded, indistinct and irregular. Osteitis refers to bone 
inflammation that appears histopathologically as a sterile 
inflammatory infiltrate. Bacterial cultures are usually 
negative [3], but low virulence microbial agents, such as   
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Propionibacterium acnes (P acnes) have been isolated in 
deep bone biopsy specimens in a few cases [6-11], and 
Staphylococcus Aureus (S. Aureus) has been isolated from a 
plantar pustule in one case [12]. 
  Bone pain and dermatologic manifestations are the most 
troublesome SAPHO syndrome symptoms [13]. Bony 
lesions manifest as severe, recurrent, debilitating pain and 
tenderness. These symptoms can be more severe at night, 
adversely affect general well-being and can have a major 
impact on the entire family. Cutaneous manifestations 
include palmoplantar pustulosis (PPP), severe forms of acne 
(acne fulminans or conglobrata, hidradenitis suppurativa) 
and various forms of psoriasis, especially pustular psoriasis 
[14]. 
  Because of misdiagnosis or lack of diagnosis, patients 
with SAPHO syndrome often receive long-term antibiotic 
therapy combined with surgical procedures, such as 
saucerisation, decortication, or partial resection of affected 
bones. However, as SAPHO syndrome etiology and 
pathophysiology are unknown, these treatment options are 
complex, uncomfortable, associated with multiple side 
effects [13,15] and ineffective in curing the disease [16-18]. 
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years; therefore early diagnosis is of great importance in 
order to avoid unnecessary procedures and promptly apply 
effective treatments. 
  To our knowledge few studies in the orthopaedic 
literature discuss osteitis or osteomyelitis in SAPHO 
syndrome [18-21]. In this report we describe the clinical, 
radiographic, and histological findings in five SAPHO 
syndrome patients. This is an attempt to increase awareness 
about SAPHO syndrome among Orthopaedic surgeons, so 
that they recognize it early when they see it. Prompt SAPHO 
syndrome recognition, followed by appropriate therapy can 
be remarkably effective, so that ineffective, unnecessary 
surgical or antibiotic therapies can be avoided. 
MATERIALS AND METHODOLOGY 
  We present data from five patients (3 women, 2 men), 
ages 27 to 44 (median 33.6) years, who were referred to the 
Orthopaedic Department outpatient clinic for evaluation of 
skeletal pain of the humerus, clavicle, sacro-pelvic joints, 
and distal radius. Data collection and publication was 
approved by the Institution Ethics Committee. Clinical and 
radiological evaluation, including X-Rays, CT or MRI scans, 
and bone scans revealed osteitis and/or hyperostosis in all 
cases. No patient had skin lesions on initial evaluation, but 
three of them developed cutaneous manifestations during the 
assessment and treatment period. Bone biopsy was done in 
two of five cases. 
  Before starting treatment, the diagnosis of SAPHO 
syndrome was established based on the diagnostic criteria 
proposed by Benhamou et al. [22]. Treatment included non 
steroid anti-inflammatory medication (lornoxicam) and 
antibiotics (Clindamycin). Demographic, clinical presentation, 
treatment and outcome data are summarized in Table 1. 
DESCRIPTION OF CASES 
Case 1 
  A 44-year-old woman suffered from recurrent right 
mandibular pain for 6 years. During these six years she 
underwent extensive diagnostic workup, including a negative 
open mandible biopsy. Due to worsening pain, she had 
biphosphonate therapy for a year, and underwent local 
excision of the right mandible lesion twice. After the 2
nd 
local excision, she was pain-free for 10 days, but then the 
pain returned. Eighteen months after her 2
nd mandible 
resection, she was referred to our orthopaedic outpatient 
clinic, for evaluation of left femur pain. Laboratory workup 
included ESR, CRP and CBC and was normal. Femur X-
Rays showed one osteosclerotic lesion with cortical 
thickening and periosteal new bone formation (Fig. 1). 
Technetium
99 scan showed multiple locations of active 
uptake, including the right mandible, anterior chest wall, left 
pubic bone and left femur. 
  She underwent open left femur biopsy and surgical 
debridement. Biopsy and cultures were negative for 
malignancy or infection. As she fulfilled the Benhamou et al. 
[22] diagnostic criteria (Table 2), the SAPHO syndrome 
diagnosis was established. Treatment included oral 
Clindamycin 400mg 3 times a day and Lornoxicam 8mg 
twice a day for 3 months. Response to treatment was 
remarkably rapid: ten days after therapy started, her pain 
resolved. On her last follow-up visit, the patient was pain-
free, 18 months after treatment started. Follow-up X-Rays of 
Table 1.  Demographic, History, Presentation, Treatment and Outcome Data 
 
Age/ 
Sex 
Symptom 
Duration 
Before 
Referral 
(Months) 
Symptomatic 
Bone Lesions 
Skin 
Lesions 
Biopsy 
Obtained  Bone Scan 
Cultures 
(Propionibacterium 
acnes) 
Treatment / 
Duration 
Length of 
Follow-Up   Outcome 
44/F 72 
R mandible 
L femur 
None 
Mandible + L 
femur, 
negative 
Multiple 
locations active 
uptake 
Negative 
Clindamycin + 
Lornoxicam/ 
3 months 
18 months  Good 
27/F 2 
R sterno-
clavicular 
joint 
R femur 
PPP 
R sterno-
clavicular 
joint, Chronic 
non-specific 
inflammatory 
changes 
R sterno-
clavicular joint + 
R femur active 
uptake 
Negative 
Clindamycin + 
Lornoxicam / 
8 months 
4 years  Good 
32/M 1  L  radius  Acne None 
Active uptake L 
distal radius + L 
sterno-clavicular 
joint 
N/A 
Clindamycin + 
Lornoxicam / 
3 months 
1 year  Good 
31/M  2  L SI joint  PPP  None 
Active uptake L 
distal radius + L 
SI joint 
N/A 
Clindamycin + 
Lornoxicam/ 
3 months 
7 months  Good 
34/F 18 
R mandible 
R femur 
None 
R mandible, 
inflammatory 
cell 
infiltration, no 
malignancy or 
infection  
Active uptake R 
femur + R 
mandible 
Negative 
Clindamycin + 
Lornoxicam / 
4 months 
1 year  Good 
R: right, L: left, PPP: palmoplantar pustulosis, SI: sacroiliac. 102    The Open Orthopaedics Journal, 2009, Volume 3  Matzaroglou et al. 
the left femur one year later showed that osteosclerosis and 
hypertrophic osteitis had improved significantly (Fig. 2). 
 
Fig. (1). Left femur X-Rays in case 1 show typical SAPHO 
osteosclerosis and hypertrophic osteitis. 
 
Fig. (2). Follow-up left femur X-Ray one year later: osteosclerosis 
and hypertrophic osteitis have improved significantly after 
treatment (case 1). 
Case 2 
  A 27-year-old woman came to the orthopaedic outpatient 
clinic for evaluation of localized swelling and tenderness 
over the right sterno-clavicular joint (Fig. 3). There were no 
signs of infection, and laboratory workup was unremarkable. 
MRI demonstrated right sterno-clavicular joint hyperostosis 
changes and bone marrow oedema. Bone scan showed right 
sterno-clavicular joint and right femur active uptake. X-Rays 
of the asymptomatic right femur showed hyperostosis in the 
diaphysis. 
 
Fig. (3). Right sterno-clavicular joint edema in a 27 year old female 
(case 2). 
  An open sterno-clavicular joint biopsy was obtained; 
pathology examination revealed chronic, non-specific 
inflammatory changes, but all cultures were negative. She 
was discharged home on Lornoxicam 8 mg p.o. twice a day, 
but episodes of swelling and pain persisted. 
  Six months later she returned for re-evaluation, because 
she developed PPP in her right foot. At that time diagnosis of 
SAPHO syndrome was established based on the Benhamou 
et al. criteria (Table 3). Treatment included oral clindamycin 
400 mg three times a day, lornoxicam 8 mg twice/day, and 
local skin therapy with topical corticosteroids (CSs) and 
psoralen-ultraviolet A (PUVA). Symptoms improved 
significantly within 3 months after treatment started. After 
continuing treatment for eight months, right sterno-clavicular 
joint swelling and tenderness had disappeared, and treatment 
stopped. The patient remained symptom-free on her last 
follow-up visit 4 years later. 
Case 3 
  A 32-year-old man was admitted to the Medicine floor 
for evaluation of fever of unknown origin, and had 
orthopaedic surgery consultation for pain at the left distal 
radius. There were no signs of local infection, and laboratory 
evaluation was unremarkable, except for moderately elevated 
ESR (35mm/1
st hour –normal is < 20mm/1
st hour). X-Rays 
revealed osteitis (osteosclerosis with homogenous fibrillary 
pattern) of the left distal radius (Fig. 4), and Technetium
99 
bone scan revealed active left distal radius and left sterno-
clavicular joint uptake. Symptoms improved after NSAID 
therapy started, and the patient went home one week later. 
  Two months later, the patient developed right foot acne 
and returned for re-evaluation. SAPHO syndrome was 
Table 2.  Diagnostic Criteria Proposed by Benhamou for SAPHO Syndrome Diagnosis [22] 
 
Inclusion Criteria  Exclusion Criteria 
Skin manifestations of severe acne  Septic osteomyelitis 
Skin manifestations of palmoplantar pustulosis  Infectious chest wall arthritis 
Hyperostosis with or without dermatosis  Infectious palmoplantar pustulosis 
Chronic recurrent multifocal osteomyelitis involving axial or peripheral skeleton, with or 
without dermatosis 
Palmoplantar keratodermia 
  Diffuse idiopathic skeletal hyperostosis 
  Osteoarticular manifestations of retinoid therapy SAPHO Syndrome: Report of Five Cases and Literature Review  The Open Orthopaedics Journal, 2009, Volume 3    103 
diagnosed, based on the Benhamou criteria (Tables 2 and 3). 
Treatment with oral Clindamycin 400 mg 3 times a day and 
Lornoxicam 8 mg twice a day started promptly and 
continued for 3 months. One year after finishing treatment, 
the patient was pain-free, without any clinical or laboratory 
abnormalities. 
 
 
Fig. (4). Left distal radius sclerosis in a 32 year-old male (case 3). 
Case 4 
  A 31-year-old man was referred to the Orthopaedic 
outpatient clinic for evaluation of left sacroiliac (SI) joint 
pain. Physical examination revealed left hand PPP. 
Laboratory workup was normal, but X-Rays revealed left SI 
joint osteitis (osteosclerosis with a homogenous fibrillary 
pattern). Bone scan showed active uptake of the left distal 
radius and left SI joint. 
  He was treated for SAPHO with oral Clindamycin 400 
mg 3 times a day and Lornoxicam 8 mg twice a day for 3 
months. At his last follow-up visit, four months after 
finishing his treatment course, he remained pain-free and 
skin lesions have resolved. 
Case 5 
  A 34-year-old woman was evaluated at an outside 
hospital for right mandible pain lasting several weeks. 
Laboratory workup (CBC, electrolytes) was unremarkable. 
X-Rays revealed diffuse right mandible cancellous bone 
sclerosis with osteolytic lesions and extensive periosteal 
reaction (Fig. 5). A mandible biopsy revealed infiltration by 
inflammatory cells, but no infection or malignancy. She 
started treatment with oral acetaminophen and NSAIDs, but 
symptoms persisted. 
 
Fig. (5). Osteolytic mandible lesions in patient 5. 
  Approximately one year later, she came to our 
orthopaedic outpatient clinic for evaluation of right femur 
pain. There were no signs of local infection, and laboratory 
workup was unremarkable. X-Rays revealed right femur 
osteitis (osteosclerosis with a homogenous fibrillary pattern). 
Technetium
99 bone scan showed active right femur and right 
mandible uptake. SAPHO syndrome was diagnosed, based 
on the Benhamou criteria (Table 2). Treatment consisted of 
oral Clindamycin 400 mg 3 times a day and Lornoxicam 8 
mg twice a day for four months. One year after completing 
her treatment course, the patient was pain-free and radiologic 
findings had improved. 
DISCUSSION 
Clinical Presentation 
  SAPHO syndrome is a complex disorder, characterized 
by peculiar combinations of bone lesions and dermatologic 
manifestations. Patients typically present with musculo-
skeletal complaints, usually of the anterior chest wall, 
synovial articulations and synchondroses. In young and 
middle-aged adults the disease is more common in the 
sterno-clavicular region (65-90% of patients), but can also 
affect the spine (33%), pelvis (13-52%) and long bones 
(30%) [5], whereas the ilium and mandible are involved in 
less than 10% of cases [3]. Various articular manifestations, 
often due to osteitis extending to adjacent articular 
Table 3.  Patient Presentation – Inclusion Criteria According to Benhamou Present in Each Case 
 
Inclusion Features – Any one of these 4 Items is Sufficient to Diagnose the Syndrome, in the Absence of an Exclusion Feature 
Case 
Skin Manifestations of Severe Acne  Skin Manifestations 
of PPP 
Hyperostosis with or 
without Dermatosis 
CRMO Involving Axial or Peripheral 
Skeleton, with or without Dermatosis 
1 No  No  Yes  Yes 
2 No  Yes  Yes  Yes 
3 Yes  No  Yes  Yes 
4 No  Yes  Yes  Yes 
5 No  No  Yes  Yes 
PPP = Palmoplantar pustulosis. 
CRMO = Chronic Recurrent Multifocal Osteomyelitis. 104    The Open Orthopaedics Journal, 2009, Volume 3  Matzaroglou et al. 
structures, especially in the sacroiliac and sterno-clavicular 
joints, may accompany the skin and bone lesions. 
  Skin involvement includes PPP, severe cystic acne and 
pustular psoriasis. Skin lesions may precede, occur concur-
rently or appear after onset of osteoarticular manifestations 
[3], but may be initially absent in 1/3 of patients [23]; 
consequently, absence of skin lesions does not exclude 
SAPHO syndrome [24]. The interval between onset of skin 
manifestations and osteoarticular lesions is generally less 
than 2 years, but intervals as long as 20 and 38 years have 
been reported [3, 25-28]. 
Diagnosis 
  Diagnosis of SAPHO syndrome is based on exclusion of 
infectious arthritis or osteomyelitis, and the presence of at 
least one of four diagnostic criteria (Table 2) proposed by 
Benhamou [22]. Consequently, SAPHO syndrome diagnosis 
is difficult in patients with a solitary symptomatic bone 
lesion, because a solitary skeletal lesion can be misdiagnosed 
as suppurative osteomyelitis, a condition with similar clinical 
and pathologic findings [14]. Conservative treatment, 
consisting of antimicrobial therapy and NSAIDs, is generally 
effective in SAPHO syndrome, without a need for invasive 
treatments [3,13,29-33]. 
  In our case series, bony lesions preceded skin 
manifestations in two cases, bony and skin lesions coexisted 
in one, whereas two patients had no skin involvement. Initial 
symptoms involved the sterno-clavicular region in 1 case, 
long bones in 3, mandible in 2 and SI joint in 1 case. The 
differential diagnosis includes tumors, infectious arthritis, 
bacterial osteomyelitis, and Paget’s disease. 
  Laboratory findings are usually of little value, and 
include mild, non-specific elevation of various inflammatory 
indices. CRP and ESR are normal or slightly elevated during 
exacerbations, but white cell count is usually normal. In 
adults with SAPHO syndrome, prevalence of the HLA-B27 
antigen is high, varying between 13% and 30% [2,3]. Our 
patients had normal laboratory findings, except for one 
patient with slightly elevated ESR. HLA-B27 testing was not 
done in any patient. 
  Radiologic findings in SAPHO syndrome include 
osteolysis (Fig. 5), osteitis (Fig. 1), hyperostosis, and 
osteosclerosis (Figs. 1, 2) [19]. Osteitis usually presents as 
osteosclerosis with homogenous fibrillary pattern [3]. 
Hyperostosis, is highly characteristic of SAPHO, and is 
characterized by chronic periosteal reaction and cortical 
thickening, resulting in bone hypertrophy. Joint erosions 
involving adjacent articulations are frequently seen as result 
of primary arthritis or extension of adjacent osteitis. CT and 
MRI are helpful in locating the lesions and providing 
information on adjacent soft tissues, but cannot distinguish 
between SAPHO lesions, osteomyelitis and malignancy 
[34,35]. Bone scintigraphy is important in diagnosing 
SAPHO syndrome, particularly for detecting early bone 
involvement [36-38]. Lesions appearing in typical sites are 
important for correct diagnosis. Bone biopsy is often used in 
an attempt to establish a diagnosis, especially in cases with 
extra-axial bone lesions, which are particularly prone to 
radiologic misdiagnosis. Bone lesion histopathology is 
variable, with early lesions characterized by the presence of 
polymorphonuclear infiltrate. An intermediate phase is 
characterized by chronic inflammation (primarily mononu-
clear cells), whereas lesions with markedly enlarged and 
sclerotic bone trabeculae and prominent marrow fibrosis are 
seen in late phases [39]. Propionibacterium acnes, a skin 
saprophyte, has been isolated from cutaneous lesions with 
severe acne and from articular and osseous lesions associated 
with pustulosis. However, most biopsies of involved areas 
demonstrate nonspecific inflammatory infiltrate [4], and 
therefore cannot confirm the diagnosis. In our series, 3 of 5 
patients underwent open lesion biopsy, but all biopsies were 
negative for malignancy, and all cultures were negative for 
bacteria. 
  As SAPHO syndrome pathogenesis remains unknown, 
two hypotheses have been proposed. According to the first 
hypothesis, bone lesions are caused by a low virulence 
pathogen transmitted via a blood-borne route. Alternatively 
an autoimmune response may be triggered by a bacterial or 
viral pathogen [40]. The second hypothesis suggests a link 
with sero-negative spondylo-arthropathies, based on the high 
frequency of axial involvement (sacroiliitis and spinal 
lesions), asymmetric paravertebral ossification (indistingui-
shable from ossification encountered in psoriatic spondy-
loarthropathy) and the possible association with psoriasis 
and inflammatory bowel (Crohn’s and ulcerative colitis) 
diseases. 
Treatment 
  Treatment options for SAPHO include NSAIDs, anti-
rheumatic drugs, such as colchicine, corticosteroids and 
biphosphonates, and disease-modifying agents, such as 
methotrexate, sulfasalazine and infliximab [29]. Biphospho-
nates, which act by inhibiting bone resorption and turnover 
[41,42], are often used as disease modifiers [15,42,43] and 
anti-inflammatory agents [44,45]. Antimicrobial therapies 
are a reasonable choice, since bacteria, such as P acnes [46] 
and Staph. Aureus [12] have been isolated in specimens from 
SAPHO patients, and have been implicated in SAPHO 
pathogenesis. Azithromycin, doxycycline, sulfamethoxazole/ 
trimetoprim and clindamycin use has been reported in 
SAPHO [12,46]. Local treatments, including local cortico-
steroid injections have also been tried. Dermatologic 
treatments include topical corticosteroids, tetracycline, other 
antimicrobial agents, psoralen-ultraviolet A (PUVA) and 
retinoinds [3]. Among all treatment options listed above, 
NSAIDS are generally considered as first-line treatment in 
SAPHO, whereas disease-modifying agents are only 
indicated when symptoms persist for at least four weeks 
despite adequate NSAID therapy. 
  In previous reports, antimicrobials were only given to a 
minority of cases [3]. Furthermore, a recent study evaluating 
the role of antibiotic therapy in SAPHO concluded that 
antibiotic therapy is effective, but SAPHO tends to relapse 
when antibiotics are discontinued after 16 weeks of 
treatment [46]. However, our limited experience on five 
cases suggests that antimicrobial therapy against P. Acnes 
could be considered first-line therapy, and might help avoid 
symptom recurrence. We believe that surgery is only 
indicated when SAPHO-induced changes adversely affect 
bone mechanics. However, surgery, such as prophylactic 
intra-medullary nailing, is also a reasonable consideration 
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fractures. In our case series, only patient #1 had surgery, but 
this operation was done in an outside hospital, before 
SAPHO syndrome was diagnosed in our clinic. 
Outcome 
  In our series, after SAPHO syndrome diagnosis was 
established, all patients promptly received treatment with 
oral NSAIDs and oral Clindamycin, while patients who 
developed dermatological manifestations also received 
topical CSs, and psoralen-ultraviolet A (PUVA). Although 
biphosphonates were not used, our results were very 
satisfactory: All patients experienced long-lasting clinical 
and radiologic improvement after 3-8 months of therapy, and 
relief persisted during long-term (4 months to 4 years, 
median 1 year) follow-up. 
CONCLUSION 
  “SAPHO syndrome” is a constellation of musculoskeletal 
disorders associated with skin conditions. Osteitis is the 
main skeletal lesion, whereas PPP and acne are important 
skin lesions. Orthopaedic surgeons should be aware of 
SAPHO syndrome, and maintain a high level of suspicion, 
especially when evaluating patients with persistent non-
specific symptoms involving the bone, joints, and/or skin. 
Prompt SAPHO syndrome recognition, followed by 
appropriate NSAID and antibiotic therapy will help avoid 
unnecessary examinations, biopsies and invasive treatments, 
and may result in long-lasting symptom relief. 
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ABBREVIATIONS 
CBC =  Complete  Blood  Count 
CRMO  =  Chronic Recurrent Multifocal Osteomyelitis 
CRP =  C-Reactive  Protein 
CSs   =  Corticosteroids 
CT =  Computerized  Tomography 
ESR =  Erythrocyte  Sedimentation  Rate 
MRI =  Magnetic  Resonance  Imaging 
NSAIDs =  Non-Steroidal  Anti-Inflammatory  Drugs 
PPP =  Palmo-Plantar  Pustulosis 
SAPHO =  Synovitis, Acne, Pustulosis, Hyperostosis and  
     Osteitis 
SI =  Sacroiliac  joint 
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